All In Biotech

Drug Trial Radar · NCT07930624

A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis

A Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis.

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Feb 15, 2027

Primary completion

May 16, 2031

Study completion May 16, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study LTS18002 is a global, multicenter, open-label (OL), Phase 3, long-term safety and efficacy extension study. The purpose of this study is to provide continued access to frexalimab for participants with MS, and to evaluate the long-term safety and efficacy profile of frexalimab. This study will monitor delayed AEs, assess the durability of safety findings and characterize any emerging safety signals that may develop over an extended follow up period. Study details include: * The study duration will be up to 4 years. * The OL treatment duration will be up to 96 weeks (corresponding to approximately 2 years) per participant. * There is an additional 24 weeks of safety follow up from the last dose of OL frexalimab for all participants (safety follow-up period/EOS: 4, 12 and 24 weeks after last investigational medicinal product(IMP) or OL frexalimab administration). * The number of visits over the 2-year duration will be dependent on subgroup assignment which is based on parent study from which the participant has entered the LTS18002 : 1. ACT16877, EFC17504, EFC18098, and ASY22814 participants * Will have on-site visits every 12 weeks (9 visits) * Additionally, there will be 16 on-site visits for OL frexalimab administration (Week 4, 8, 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, and 92) for all participants EXCEPT those entering from EFC18098 (frexalimab open label administration is conducted at home via SC large volume (OBDS VT) device) * There will be 3 follow up visits beginning 4 weeks after the last administration of OL frexalimab * Home administration is allowed for participants from ACT16877, based on Investigator judgement, participant/caregiver training and local availability. Home nurse services are mandatory for at-home administration. * Home nurse services for at home administration may be considered for EFC17504 participants after Week 24 administration of OL frexalimab, based on availability. Participants that have initiated OL frexalimab via home administration during the parent study may continue to receive it in this manner. * NOTE: For participants from EFC17504, all on-site visits including monthly IMP administrations will include safety labs (biochemistry, hematology liver chemistry, and immunoglobulins) and physical exams 2. EFC17919A/B participants * Will have on site visits every 12 weeks (9 visits) * Will have a total of 16 visits for OL frexalimab administration (Week 4, 8, 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, and 92) * Additionally, there will be up to 3 visits for administration of DB treatment (until results become available and randomization assignment availability). * Home nurse services for at home administration may be considered for EFC17919A/B participants after Week 24 administration of OL frexalimab, based on availability. NOTE: all on-site visits including monthly IMP administrations will include safety labs (biochemistry, hematology liver chemistry, and immunoglobulins) and physical exams.

Conditions

  • Multiple Sclerosis

Interventions

  • FrexalimabDrug

    Pharmaceutical form:Solution for injection-Route of administration:SC

  • FrexalimabDrug

    Pharmaceutical form:Solution for infusion-Route of administration:IV

  • Frexalimab PlaceboDrug

    Pharmaceutical form:Solution for infusion-Route of administration:IV

  • TeriflunomideDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • Teriflunomide PlaceboDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • MRI contrast-enhancing agentsDrug

    Route of administration:IV

  • CholestyramineDrug

    Route of administration:oral

  • charcoalDrug

    Route of administration:oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events(AEs)Time frame: up to to approximately 2.5 years since last participant in

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.